RNP-Sm Antibody

Blood

Report in 48Hrs

At Home

No Fasting Required

Details

Autoantibody test.

₹2,102₹3,002

30% OFF

RNP-Sm Antibody Test Information Guide

Why is it done?
- Detects antibodies against ribonucleoprotein (RNP) and Smith (Sm) antigens, which are autoimmune markers found in the body's nuclear material
- Primary indication: Diagnosis and evaluation of Systemic Lupus Erythematosus (SLE), particularly to distinguish SLE from other autoimmune connective tissue diseases
- Ordered when patients present with symptoms suggestive of autoimmune disease such as joint pain, rash, fever, and photosensitivity
- Used to assess disease activity and predict clinical outcomes in patients with established SLE and mixed connective tissue disease (MCTD)
- Typically performed during initial diagnostic workup or when autoimmune disease is suspected; may be repeated to monitor disease progression
Normal Range
- Negative Result: <0.9 Index (or negative interpretation based on laboratory methodology)
- Borderline Result: 0.9-1.0 Index (may warrant repeat testing or clinical correlation)
- Positive Result: >1.0 Index (indicates presence of RNP-Sm antibodies)
- Units: Index values or titers; some laboratories report as positive/negative or weakly positive/moderately positive/strongly positive
- Normal interpretation: Negative or absent antibodies indicate no autoimmune markers detected; abnormal results suggest presence of autoimmune antibodies
- Note: Specific reference ranges may vary by laboratory and testing methodology (ELISA, immunofluorescence, or multiplex assays)
Interpretation
- Negative Result: Suggests absence of RNP-Sm autoimmune markers; does not exclude SLE or other autoimmune diseases, as some patients may have other autoantibodies
- Positive RNP antibodies: Highly specific indicator of SLE; present in approximately 25-40% of SLE patients; particularly associated with undifferentiated connective tissue disease (UCTD) and mixed connective tissue disease
- Positive Sm antibodies (Smith): Highly specific for SLE; present in 20-30% of SLE patients; considered a major criterion for SLE diagnosis per ACR/EULAR guidelines
- High titers: May correlate with more active disease, greater disease severity, and increased risk of organ involvement including renal or cardiac complications
- Factors affecting results: Test methodology, presence of other autoimmune conditions, recent immunosuppressive therapy, pregnancy, infections, and malignancies may influence antibody levels
- Clinical significance: Must be interpreted in context with clinical presentation, other laboratory markers (ANA, anti-dsDNA, complement levels), and diagnostic criteria; positive results support but do not definitively confirm SLE diagnosis
- Persistently positive antibodies: Associated with persistent disease activity; may indicate need for continued immunosuppressive therapy
Associated Organs
- Primary System: Autoimmune/Connective Tissue System - affects multiple organ systems through autoimmune mechanisms
- Kidneys: Lupus nephritis is a major complication in RNP-Sm positive patients, potentially leading to glomerulonephritis and renal failure
- Heart: Pericarditis, myocarditis, valvular disease, and accelerated atherosclerosis are associated risks; increased cardiovascular mortality
- Lungs: Pulmonary manifestations including pleural effusion, pulmonary fibrosis, pulmonary hypertension, and acute respiratory distress syndrome
- Joints: Arthritis and arthralgia, particularly affecting small joints of hands and feet; may progress to erosive disease
- Skin: Malar rash, photosensitive rash, discoid lesions, and oral ulcers commonly observed in SLE
- Central Nervous System: Neuropsychiatric lupus manifestations including cognitive dysfunction, seizures, psychosis, and aseptic meningitis
- Blood: Cytopenias including thrombocytopenia, hemolytic anemia, and leukopenia; increased thrombotic risk
- Associated Conditions: Systemic Lupus Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD), Undifferentiated Connective Tissue Disease (UCTD), Sjögren's syndrome, and rheumatoid arthritis
Follow-up Tests
- Antinuclear Antibody (ANA): Screen test that should precede RNP-Sm testing; positive ANA often prompts RNP-Sm reflex testing
- Anti-dsDNA (Double-Stranded DNA) Antibodies: Highly specific for SLE; often used in conjunction with RNP-Sm to confirm diagnosis
- Complement Levels (C3, C4): Assess disease activity; low levels correlate with active lupus and renal involvement
- Complete Blood Count (CBC): Detect cytopenias associated with SLE including thrombocytopenia and hemolytic anemia
- Renal Function Tests: Creatinine, BUN, and urinalysis to screen for lupus nephritis; baseline assessment crucial
- Urinalysis with Microscopy: Detect proteinuria, hematuria, and casts suggestive of renal involvement
- 24-Hour Urine Protein: Quantify proteinuria if lupus nephritis suspected; important for prognosis and treatment decisions
- Erythrocyte Sedimentation Rate (ESR): Nonspecific marker of inflammation; elevated in active SLE
- C-Reactive Protein (CRP): Assess acute phase inflammation; may be relatively normal in SLE despite active disease
- Liver Function Tests: Screen for hepatic involvement and assess baseline function before immunosuppressive therapy
- Lupus Anticoagulant and Anticardiolipin Antibodies: Assess thrombotic risk if indicated by clinical presentation
- Other Autoantibodies: Anti-SSA/Ro, Anti-SSB/La, anti-centromere, and ANCA if clinical features suggest alternative diagnoses
- Monitoring frequency: RNP-Sm titers may be repeated every 3-6 months during active disease or when adjusting therapy; less frequently during remission
- Imaging Studies: Chest X-ray, echocardiography, and renal ultrasound as clinically indicated to assess organ involvement
Fasting Required?
- Fasting Required: No - This is a serum antibody test that does not require fasting
- Blood Collection: Simple venipuncture; patient may eat and drink normally before the test
- Medications: No specific medications need to be avoided; continue all routine medications including immunosuppressive agents unless otherwise instructed
- Patient Preparation: Wear comfortable, loose-fitting clothing with short or rolled-up sleeves to facilitate blood draw; arrive hydrated
- Timing Considerations: Test can be performed at any time of day; no specific time restriction
- Special Instructions: Inform healthcare provider of all current medications, supplements, and recent illnesses; report any bleeding disorders or anticoagulation therapy
- Results Timeline: Typically available within 1-3 business days depending on laboratory; may be expedited if urgent clinical indication

How our test process works!